Structure via PubChem · Public domain (PubChem)
miridesap
Sign in to saveAlso known as compound 52 [PMID 14998318], GSK2315698, Ro 63-8695, CPHPC, 1,1'-hexanedioyldi-D-proline
CPHPC ((R)-1-{6-[(R)-2-carboxypyrrolidin-1-yl]-6-oxohexanoyl}pyrrolidine-2-carboxylic acid) is a proline-derived small molecule able to strip amyloid P (AP) from deposits by reducing levels of circulating serum amyloid P (SAP). The SAP-amyloid association has also been identified as a possible drug target for anti-amyloid therapy, with the recent development and first stage clinical trials of CPHPC for amyloidosis.
In the Vinony graph
Vinony's link graph records 2 inbound references to miridesap, and connects out to Alzheimer's disease, digital object identifier and chemical formula.
Vinony files it under Alpha-Amino acids, Amino acid derivatives and Chembox image size set.
Vinony links it to 5 Wikipedia language editions.
Chemical data
- Formula
- C16H24N2O6
- Molecular weight
- 340.37 g/mol
- IUPAC name
- (2R)-1-[6-[(2R)-2-carboxypyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylic acid
- SMILES
- C1C[C@@H](N(C1)C(=O)CCCCC(=O)N2CCC[C@@H]2C(=O)O)C(=O)O
- InChIKey
- HZLAWYIBLZNRFZ-VXGBXAGGSA-N
- XLogP
- 0
- Polar surface area
- 115 Ų
- H-bond donors
- 2
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- HIV infection, amyloidosis, primary systemic amyloidosis
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 340.163
Show 3 more facts
- chemical formula
- C₁₆H₂₄N₂O₆
- isomeric SMILES
- C1C[C@@H](N(C1)C(=O)CCCCC(=O)N2CCC[C@@H]2C(=O)O)C(=O)O
- canonical SMILES
- C1CC(N(C1)C(=O)CCCCC(=O)N2CCCC2C(=O)O)C(=O)O
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- Mechanism
- References
CPHPC ((R)-1-{6-[(R)-2-carboxypyrrolidin-1-yl]-6-oxohexanoyl}pyrrolidine-2-carboxylic acid) is a proline-derived small molecule able to strip amyloid P (AP) from deposits by reducing levels of circulating serum amyloid P (SAP). The SAP-amyloid association has also been identified as a possible drug target for anti-amyloid therapy, with the recent development and first stage clinical trials of CPHPC for amyloidosis.
CPHPC has also been patented for possible treatment of Alzheimer's disease.
Excerpted from Wikipedia’s “miridesap” article, available under the CC BY-SA 4.0 licence.